The Functional Assessment of Cancer Therapy - Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 9, 2004, Pages 11-15

  Cella, David ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE COURSE; EVALUATION; HUMAN; INFORMATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; VALIDATION PROCESS;

EID: 3042714190     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.04.008     Document Type: Article

References (15)

1. Jacobsen P.B., Weitzner M.A. Evaluation of palliative endpoints in oncology clinical trials. Cancer Control. 6:1999;471-477
2. Earle C.C., Evans W.K. Management issues for stage IV non - small-cell lung cancer. Cancer Control. 4:1997;307-316
3. Cella D.F., Bonomi A.E., Lloyd S.R., et al. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer. 12:1995;199-220
4. Jagasia M., Johnson D.H., Hande K.R., et al. Quality of life (QOL) predicts response to therapy and improves during the treatment of non - small cell lung cancer (NSCLC) patients with paclitaxel (P) and carboplatin (C). Proc Am Soc Clin Oncol. 17:1998;466a. (abstr 1791)
5. Barsevick A., Langer C., Brunet D., et al. Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non - small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel. Proc Am Soc Clin Oncol. 16:1997;44a. (abstr 153)
6. Cella D., Eton D.T., Fairclough D.L., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 55:2002;285-295
7. Montazeri A., Milroy R., Hole D., et al. Quality of life in lung cancer patients As an important prognostic factor. Lung Cancer. 31:2001;233-240
8. Cella D., Fairclough D.L., Bonomi P.B., et al. Quality of life (QOL) in advanced non - small cell lung cancer (NSCLC) Results from Eastern Cooperative Oncology Group (ECOG) study E5592. Proc Am Soc Clin Oncol. 16:1997;2a. (abstr 4)
9. Bottomley A. The cancer patient and quality of life. Oncologist. 7:2002;120-125
10. John L.D. Quality of life in patients receiving radiation therapy for non - small cell lung cancer. Oncol Nurs Forum. 28:2001;807-813
11. Langendijk J.A., Aaronson N.K., de Jong J.M., et al. Prospective study on quality of life before and after radical radiotherapy in non - small-cell lung cancer. J Clin Oncol. 19:2001;2123-2133
12. Hollen P.J., Gralla R.J. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol. 23:1996;31-40
13. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale Development and validation of the general measure. J Clin Oncol. 11:1993;570-579
14. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non - small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 18:2000;623-631
15. Baselga J., LoRusso P., Herbst R., et al. A pharmacokinetic/ pharmacodynamic trial of ZD1839 (IRESSA), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment. Clin Cancer Res. 5:(suppl):1999;3735s. (abstr)